Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma

Thomas, Giovana R.; Nadiminti, Hari; Regalado, Jacinto

doi:10.1111/j.0959-9673.2005.00447.x

Cited by 180 publications

(194 citation statements)

References 186 publications

Supporting

Mentioning

165

Contrasting

Unclassified

Order By: Relevance

“…This has promoted extensive investigation into a great variety of tissue biomarkers for their suitability as molecular indicators of clinical outcome in patients. 30 However, an appropriate marker to predict response to chemotherapy has not been described so far.…”

Section: Discussionmentioning

confidence: 99%

STAT1 activation in squamous cell cancer of the oral cavity

Laimer¹,

Spizzo²,

Obrist³

et al. 2007

Cancer

View full text Add to dashboard Cite

Thermal degradation of poly(dimethylsilylene) homopolymer (PDMS) and poly(tetramethyldisilylene‐co‐styrene) copolymer (PTMDSS) was investigated by pyrolysis‐gas chromatography and thermogravimetry (TG). PDMS decomposes by depolymerization, producing linear and cyclic oligomeric products, whereas PTMDSS decomposes by random degradation along the chain resulting in each monomeric product and various other combination products. The homopolymer was found to be much less stable than the copolymer. The decomposition mechanisms leading to the formation of various products are shown. The kinetic parameters of thermal degradation were evaluated by different integral methods using TG data. The activation energies of decomposition (E) for the homopolymer and the copolymer are found to be 122 and 181 kJ/mol, respectively, and the corresponding values of order of reaction are 1 and 1.5. The observed difference in the thermal stability and the values of the kinetic parameters for decomposition of these polymers are explained in relation with the mechanism of decomposition. © 2005 Wiley Periodicals, Inc. J Appl Polym Sci, 2006

show abstract

Section: Discussionmentioning

confidence: 99%

STAT1 activation in squamous cell cancer of the oral cavity

Laimer¹,

Spizzo²,

Obrist³

et al. 2007

Cancer

View full text Add to dashboard Cite

show abstract

“…Molecular identification of tissue biomarkers in diagnostic biopsy specimens may not only identify patients at risk for developing of HNSCC but it may also select patients that benefit from more aggressive treatment modalities (Thomas et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

HER2/neu Expression in Head and Neck Squamous Cell Carcinoma Patients is not Significantly Elevated

Sardari¹,

Pardis²,

Andisheh-Tadbir³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: HER2/neu, a member of EGFR family, is over expressed in some tumors .The purpose of this study was to determine the salivary level and tissue expression of HER2/neu in patients with head and neck squamous cell carcinoma (HNSCC) and any correlation with clinicopathologic parameters. Methods: An enzymelinked immunosorbent assay (ELISA) was used to evaluate the salivary level and immunohistochemistry (IHC) to assess tissue expression of HER2/neu in 28 patients with HNSCC and 25 healthy controls. Results: The salivary levels of HER2/neu in HNSCC patients was not significantly higher than in the healthy controls (p>0.005). There was no apparent correlation in salivary HER2/neu level with clinicopathological features such as age, sex, grade, tumor size and nodal status. All HNSCC specimens were positive (membranous or/and cytoplasmic) for HER2/ neu, except one sample. Only one HNSCC specimen was stained in cytoplasm purely. All control specimens were membranous and cytoplasmic positive for HER2/neu. There was a significant difference between cytoplasmic staining in case and control groups (p-value<0.05). Conclusion: In our cases, no overexpression of HER2/neu was observed. Thus, our findings suggested that the use of Her-2 as a salivary marker of HNSCC cannot be recommended.

show abstract

“…An additional concern is that severe cosmetic deformity may result from wide surgical resection. 2 Standard therapy for early stage cancer is surgical resection with or without post-operative radiation therapy. 3 Therapy for advanced stage cancer is chemotherapy and/or radiation therapy with or without surgical resection.…”

Section: Introductionmentioning

confidence: 99%